Welcome to Carbon13’s podcast “Climate Takes” where we ask founders, investors and builders for their “takes” on their industry and climate challenge, as well as setting a call to action, asking what will it take to solve the climate emergency?
On Climate Takes Synthetic Biology, we’re joined by Manuel Rios Krauss and Tim Corcoran of Deep Blue Biotech who give their takes on why the bioeconomy has trillion dollar potential, but comes with serious challenges for founders trying to move this technology forward.
“Everything’s that’s around us is either the biological world or things created by our intellect. Those two things are going to be disrupted by AI and synthetic biology. So we’re coming at the crossroads of a major revolution that is going to change almost everything we know”
About the episode
Manuel and Tim take us through Deep Blue Biotech’s work, using synthetic biology to produce green chemicals. In particular we look at the commercial journey of the company: how they identified their beachhead product and market, how corporates view their research activities, and how they raised capital from investors such as SFC Capital and One Planet Capital, no mean feat for an early stage IP-led venture.
In climatetech, synthetic biology’s potential to replace fossil fuels or reduce habitat destruction such as deforestation is well documented. The bioeconomy is projected to hit $30 trillion by 2050, but there are a lot of pitfalls along the way – startups like Deep Blue Biotech still have to meet the golden triangle of cost parity, better performance, and a significant impact on the climate.
Also on Climate Takes
We ask special guests for their “takes” on their industry and climate challenge, as well as setting a call to action, asking what will it take to solve the climate emergency?